The New England journal of medicine 2016-11-10
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Abstract
Background
Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).
Methods
In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety.
Results
Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%).
Conclusions
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Related Questions
How do you treat Stage IIIC T4N3 NSCLC?
Probably need a bit more information since T4 is fairly heterogeneous, but it is absolutely treatable. If it involves both ipsilateral lobes, then SBRT to one isolated lesion and CRT for the rest is one approach. If T4 is involved in critical mediastinal organs, probably some induction therapy with ...
What are your treatment considerations for a patient with stage IVb NSCLC who is KRAS G12C mutated and PD-L1 high (>50%)?
Assuming that this is in the treatment naïve scenario, we have a lot of options in this case. The patient could be considered single agent immunotherapy or chemo-immunotherapy or clinical trials for KRAS G12C. While we need more prospective data on this topic, I still look at the co-mutations (i.e.,...
Do the results of CheckMate 451 (nivo-ipi or nivo maintenance after chemotherapy in patients with SCLC) raise any questions for you about the role of immunotherapy in SCLC as established by the CASPIAN and IMpower 133 trials?
The results of the Checkmate 451 trial evaluating nivolumab and ipilimumab or nivolumab maintenance versus no maintenance following front line chemotherapy for extensive stage small cell lung cancer help put the CASPIAN and IMpower 133 trials using front line chemotherapy with immune checkpoint inhi...
How do you decide between checkpoint monotherapy versus chemo-immunotherapy approach for patients with PD-L1 High (>50%) NSCLC?
At this point, there are no prospective trials comparing checkpoint monotherapy and chemo-immunotherapy for patients with PD-L1 high NSCLC. The ongoing prospective INSIGNA trial will answer this question. If one does a cross trial comparison of pembrolizumab for patients with PD-L1 of >50% and chemo...
How do you decide which immunotherapy agent to utilize for 1st line in PD-L1 high (>50%) NSCLC?
Now with the approval of atezolizumab based on the positive Impower110 study (led by @Dr. First Last and @Dr. First Last), we have 2 frontline checkpoint inhibitors to choose from. Indeed the data appears very convincing for both, therefore on scientific grounds, I would not be able to choose one ve...
How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?
Patients with metastatic lung cancer are at increased risk of thromboembolic events with an estimated frequency of 13.9% (Connolly et al., PMID 23026639). Preclinical data show that PD-1/PD-1 pathway blockade may lead to increased levels of pro-inflammatory cytokines and T cell driven progression an...
Is there any evidence that patients with metastatic NSCLC with KRAS G12C mutations benefit less from treatment with immunotherapy?
KRAS mutation in NSCLC has been associated with improved response rate and overall survival compared to KRAS wild type NSCLC in meta-analysis of single-agent, second-line trials with PD-1/PD-L1 inhibition. Moreover, analysis of patients with KRAS lung adenocarcinoma divided by subsets including co-m...
How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?
This interesting case brings up how to separate in our work fact from fiction. We are presented with a case of a patient with metastatic non-squamous non-small cell lung cancer with a PD-L1 TPS score of 55% and ERBB2 amplification by Foundation One testing.What is the right approach? Standard chemo/...
How would you treat a metastatic lung adenocarcinoma with MET exon 14 skip mutation on ctDNA, negative tissue NGS and PD-L1 of >50%?
I would treat this patient with single-agent pembrolizumab. If they had rapidly progressing disease with worsening symptoms or if they were a never smoker, I would favor carboplatin/pemetrexed/pembrolizumab in order to optimize rapidity of response. These recommendations are based on the results of ...
Are there subsets of patient in which you would choose chemotherapy+pembrolizumab vs pembrolizumab monotherapy in metastatic NSCLC?
My take on what to do in the >50% PD-L1 patients from an unapologetic cross-trial comparison of KEYNOTE-024 and the 50% subgroup of KEYNOTE-189: mPFS: 10.3 in KN24, 9.4 in KN189PFS at 12 months: 48% in KN24, 45% in KN189OS at12 months: 70% in KN24, 73% in KN189 Thus, I think chemo does not add anyth...
What is the role of upfront pembrolizumab in metastatic PD-L1 positive NSCLC presenting with SVC syndrome?
This is a "trick question" as there are at least 3 difficult questions hidden here- Can systemic therapy replace the need for local therapy in urgent clinical situations traditionally calling for radiation? What is the best upfront treatment regimen for a patient with PD-L1 positive NSCLC? What is t...
How would you treat a patient with metastatic NSCLC >50% PDL-1 positive AND an EGFR or ALK gene mutation/rearrangement in the first-line setting?
There have been multiple reports showing a positive association between EGFR activation (through mutational activation and/or signaling) and PDL1 expression (e.g. J Thorac Oncol 2015 Jun;10(6):910-23). Similarly, there are some reports of a similar association with ALK translocation (e.g. Clin Cance...
Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?
Though some clinicians have been exploring the idea of targeted therapy for EGFR mutant brain metastases, this has been done in the absence of strong evidence. Reasons for pushing this idea are that sometimes the lesions seem to respond, and this has been seen in some single arm studies and anecdota...